Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 196

1.

Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.

Graves J, Galetta SL, Palmer J, Margolin DH, Rizzo M, Bilbruck J, Balcer LJ.

Mult Scler. 2013 Sep;19(10):1302-9. doi: 10.1177/1352458513475722. Epub 2013 Mar 4.

2.

Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Bass AD, Wynn DR, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Lancet Neurol. 2011 Apr;10(4):338-48. doi: 10.1016/S1474-4422(11)70020-5.

PMID:
21397567
3.

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA; CARE-MS II investigators.

Lancet. 2012 Nov 24;380(9856):1829-39. doi: 10.1016/S0140-6736(12)61768-1. Epub 2012 Nov 1.

PMID:
23122650
4.

Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA; CARE-MS I investigators.

Lancet. 2012 Nov 24;380(9856):1819-28. doi: 10.1016/S0140-6736(12)61769-3. Epub 2012 Nov 1.

PMID:
23122652
5.

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

CAMMS223 Trial Investigators, Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, Norris K, Tandon PK.

N Engl J Med. 2008 Oct 23;359(17):1786-801. doi: 10.1056/NEJMoa0802670.

6.

Alemtuzumab: evidence for its potential in relapsing-remitting multiple sclerosis.

Brown JW, Coles AJ.

Drug Des Devel Ther. 2013;7:131-8. doi: 10.2147/DDDT.S32687. Epub 2013 Mar 6. Review.

7.

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial.

Coles AJ, Fox E, Vladic A, Gazda SK, Brinar V, Selmaj KW, Skoromets A, Stolyarov I, Bass A, Sullivan H, Margolin DH, Lake SL, Moran S, Palmer J, Smith MS, Compston DA.

Neurology. 2012 Apr 3;78(14):1069-78. doi: 10.1212/WNL.0b013e31824e8ee7. Epub 2012 Mar 21.

PMID:
22442431
8.

Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis.

Daniels GH, Vladic A, Brinar V, Zavalishin I, Valente W, Oyuela P, Palmer J, Margolin DH, Hollenstein J.

J Clin Endocrinol Metab. 2014 Jan;99(1):80-9. doi: 10.1210/jc.2013-2201. Epub 2013 Dec 20.

PMID:
24170099
9.

Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.

Balcer LJ, Galetta SL, Polman CH, Eggenberger E, Calabresi PA, Zhang A, Scanlon JV, Hyde R.

J Neurol Sci. 2012 Jul 15;318(1-2):119-24. doi: 10.1016/j.jns.2012.03.009. Epub 2012 Apr 21.

PMID:
22521274
10.

Natalizumab reduces visual loss in patients with relapsing multiple sclerosis.

Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA.

Neurology. 2007 Apr 17;68(16):1299-304.

PMID:
17438220
11.

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Hersh CM, Cohen JA.

Immunotherapy. 2014;6(3):249-59. doi: 10.2217/imt.14.7. Review.

PMID:
24762071
12.

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

Jones JL, Anderson JM, Phuah CL, Fox EJ, Selmaj K, Margolin D, Lake SL, Palmer J, Thompson SJ, Wilkins A, Webber DJ, Compston DA, Coles AJ.

Brain. 2010 Aug;133(Pt 8):2232-47. doi: 10.1093/brain/awq176. Epub 2010 Jul 21.

13.

Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing-remitting multiple sclerosis.

Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, Zhu H, Markovic-Plese S.

J Immunol. 2013 Dec 15;191(12):5867-74. doi: 10.4049/jimmunol.1301926. Epub 2013 Nov 6.

14.

The outlook for alemtuzumab in multiple sclerosis.

Williams T, Coles A, Azzopardi L.

BioDrugs. 2013 Jun;27(3):181-9. doi: 10.1007/s40259-013-0028-3.

PMID:
23558379
15.

Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis.

Hartung HP, Aktas O, Boyko AN.

Mult Scler. 2015 Jan;21(1):22-34. doi: 10.1177/1352458514549398. Epub 2014 Oct 24. Review.

16.

Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.

Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M.

Mult Scler. 2010 Jul;16(7):848-54. doi: 10.1177/1352458510369147. Epub 2010 May 20.

PMID:
20488825
17.

Spotlight on alemtuzumab.

Jones JL, Coles AJ.

Int MS J. 2009 Sep;16(3):77-81. Review.

PMID:
19878629
18.

Current evaluation of alemtuzumab in multiple sclerosis.

Coyle PK.

Expert Opin Biol Ther. 2014 Jan;14(1):127-35. doi: 10.1517/14712598.2014.866084. Epub 2013 Dec 2.

PMID:
24289293
19.

Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis.

Patti F, Amato MP, Bastianello S, Caniatti L, Di Monte E, Ferrazza P, Goretti B, Gallo P, Morra VB, Lo Fermo S, Picconi O, Tola MR, Trojano M; COGIMUS Study Group.

Mult Scler. 2010 Jan;16(1):68-77. doi: 10.1177/1352458509350309. Epub 2009 Dec 7.

PMID:
19995846
20.

Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.

Zivadinov R, Dwyer MG, Hussein S, Carl E, Kennedy C, Andrews M, Hojnacki D, Heininen-Brown M, Willis L, Cherneva M, Bergsland N, Weinstock-Guttman B.

Mult Scler. 2012 Aug;18(8):1125-34. doi: 10.1177/1352458511433304. Epub 2011 Dec 22.

PMID:
22194217
Items per page

Supplemental Content

Write to the Help Desk